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The clinical outcome of hematopoietic stem cell transplantation (HSCT) for patients with b-thalassemia major
(b-TM) can be affected by several factors. We investigated the inﬂuence of b-globin gene mutation in patients
with b-TM on the clinical outcome of HSCT and conducted a prospective study of consecutive b-TM patients
who underwent allogeneic HSCT at our center. Among 87 included patients, 62 (71%) had homozygous and 25
(29%) had compound heterozygous b-globin gene mutations. Intervening sequence II-1 appeared to be the
most common mutation, with an occurrence rate of 33% in b-globin alleles. With a median follow-up of 12
months, the thalassemia-free survival and overall survival probabilities were 83% (standard error, 4%) and 90%
(standard error, 3%), respectively. Overall survival was not found to be associated with the b-globin gene
mutation status, but thalassemia-free survival was signiﬁcantly improved in patients with homozygous
mutations compared with patients with compound heterozygous mutations in univariate (91.2% versus 64.0%,
P ¼ .009) and multivariable (hazard ratio, 3.83; P ¼ .014) analyses. This is the ﬁrst report on the impact of b-
globin mutation status on the outcome of b-TM after allogeneic HSCT and helps to better illustrate the course
and prognosis of b-TM after transplantation.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
b-thalassemia major (b-TM) is a hereditary anemia
caused by mutation of the b-globin gene that is character-
ized by absent or defective b-globin chain synthesis,
resulting in ineffective erythropoiesis [1]. Approximately
300 different mutations in the b-globin gene are respon-
sible for b-TM; these mutations are mostly point mutations
within the b-globin gene itself or in its immediate ﬂanking
sequence [2]. In most cases, b-TM patients become
dependent of transfusions during the ﬁrst 6 months of their
lives because of a decrease in the expression of g-globin
genes. Although the life expectancy of b-TM patients
has increased over the past few decades owing to chronic
blood transfusions and iron chelation therapy, these
treatments do not cure the disease. Hematopoietic stem
cell transplantation (HSCT) has been used since the earlyedgments on page 1776.
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14.07.0041980s for the treatment of b-TM and remains the only
potentially curative treatment for these patients [3-8].
Although HSCT showed excellent results for these patients
[9-11], different centers reported disparate outcomes for
these patients [12-14].
Genetic proﬁling has proven to be 1 of the most valuable
prognostic determinants in hematologic diseases. For
example, in Fanconi anemia, the mutation type in FANCA
gene has been shown to be associated with clinical outcome
[15]. In b-TM, the genetic heterogeneity has been suggested
to be associated with disease severity [16,17]. However, the
molecular or genetic determinants of HSCT outcome in b-TM
have not been investigated. We hypothesized that such
determinants account for some of the disparities in trans-
plantation outcomes. Therefore, we conducted a study to
investigate the effects of type of b-globin mutation on HSCT
outcomes in patients with b-TM. To our knowledge, this is
the ﬁrst report on the prognostic signiﬁcance of b-globin
gene mutation status on the outcome of subsequent trans-
plantation procedures in b-TM patients. Our data suggest
that b-globin gene mutation may be responsible for the
signiﬁcant heterogeneity in transplantation outcome in b-TM
patients.Transplantation.
Table 1
Clinical Characteristics of Patients and Transplantations
Characteristic Value
No. of patients 87
Patient age, median (range), yr 8 (2-15)
Sex
Male 49 (56)
Female 38 (44)
Pesaro classiﬁcation*
I 26 (30)
II 38 (44)
III 23 (26)
b-Globin gene mutation
Homozygous 62 (71)
Compound heterozygous 25 (29)
Donor age, median (range), yr 13.5 (2.5-53)
Donor sex
Male 46 (53)
Female 41 (47)
Donor-recipient sex
Matched 44 (51)
Unmatched 43 (49)
Donor-recipient relationship
Sibling 75 (86)
Other relative 12 (14)
Donor-recipient age difference
Donor younger than recipient 27 (31)
Donor older than recipient <12 yr 31 (36)
Donor older than recipient 12 yr 29 (33)
Source of cells
Peripheral blood 57 (66)
Bone marrow 30 (34)
Chimerism
Full donor 77 (89)
Mixed 3 (3)
Graft rejection 7 (8)
Acute GVHD 39 (45)
I-II 22 (56)
III-IV 17 (44)
Chronic GVHD 14 (16)
Limited 12 (86)
Extensive 2 (14)
Data presented are n (%), unless otherwise indicated.
* From Lucarelli at al. N Engl J Med, 1990. [7]
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This study was approved by the institutional review board of He-
matology Oncology and Stem Cell Transplantation Research Center.
Because all of the study participants were children, written informed
consent was obtained from their parents or legal guardians before study
admission in accordance with the Declaration of Helsinki. All patients
with b-TM who underwent HSCT between November 2009 and
November 2011 were assessed for study eligibility. Patients who had
cardiac or pulmonary diseases, human immunodeﬁciency virus, hepa-
titis B virus, hepatitis C virus, or progressive cirrhosis were excluded
from the study. All patients underwent liver biopsy to determine liver
ﬁbrosis stage and were classiﬁed in risk class I, II, or III using the Pesaro
classiﬁcation.
All patients received stem cell transplants from an HLA-identical related
donor, with bone marrow or peripheral blood as a stem cell source. Sibling
donors werematched at low resolution for HLA-A, -B, and -DR. Other related
donors were matched at 10/10 loci by high-resolution typing. The donors
had normal physical examination and blood test results and negative
serology for human immunodeﬁciency virus and hepatitis viruses. The
conditioning regimen administered before transplantation was based on
conventional protocols described previously [11,18,19]. Brieﬂy, for patients
in Pesaro risk class I and II, the conditioning regimenwas busulfan at 3.5 mg/
kg/day from day -9 for 4 consecutive days, cyclophosphamide at 50 mg/kg/
day as intravenous infusion from day -5 for 4 consecutive days, and rabbit
antithymocyte globulin (Thymoglobulin, Genzyme, Cambridge, MA) at
1.25 mg/kg/day as intravenous infusion from day -3 for 2 consecutive days.
The conditioning regimen for patients in risk class III consisted of busulfan at
3.5 mg/kg/day from day -9 for 4 consecutive days and cyclophosphamide at
40 mg/kg/day from day -5 for 4 consecutive days. Prophylaxis against graft-
versus-host disease (GVHD) consisted of cyclosporine (1.5 mg/kg/day
intravenously, from day -2 and then 3 mg/kg/day from day 7) with a short
course of methotrexate (10 mg/m2 on day 1 and 6 mg/m2 on days 3, 6, and
11). Cyclosporine was continued orally for 6 to 7 months after HSCT and was
discontinued in the absence of GVHD.
All patients were hospitalized in well-restricted and protective isolation
and fed via hyperalimentation. The patients were checked for infections,
cytomegalovirus DNA (using polymerase chain reaction analysis), or cyto-
megalovirus structural protein 65 antigen twice weekly. The patients also
were given acyclovir and ﬂuconazole to prevent viral and fungal infections,
as well as sulfamethoxazole/trimethoprim to prevent Pneumocystis jirovecii.
All patients had taken phenytoin for prophylaxis of busulfan-induced
seizure.
Genotypic Analysis
Blood samples were collected in EDTA-containing tubes. DNA was
extracted from blood samples using a standard salting out method [20].
Because b-globin mutations usually arise at multiple geographical locations
and there are certain mutations accounting for the majority of thalassemia
major in each location, the ampliﬁcation refractory mutation system tech-
nique using primer sequences was used to detect common b-TM mutations
[21,22]. DNA sequencing and multiplex ligation probe ampliﬁcation were
used when no mutation was detected with the ampliﬁcation refractory
mutation system.
Additionally, alpha-globin genes were analyzed by multiplex gapePCR
to detect common deletions. When no abnormalities were detected,
multiplex ligation-dependent probe ampliﬁcation assay was performed to
detect other molecular alterations.
Endpoints
Outcome endpoints followed standard deﬁnitions. Myeloid engraft-
ment was deﬁned as the ﬁrst of 3 consecutive days in which the absolute
neutrophil cell count was .5  109/L, and platelet recovery was deﬁned
as platelets 20  109/L without transfusion support for 7 days. Acute
grade II to IV GVHD and chronic GVHD were graded using standard
criteria [23,24]. Overall survival (OS) was deﬁned as the time from
transplantation until death from any cause or the last follow-up for sur-
viving patients. Thalassemia-free survival (TFS) was deﬁned as the time
from transplantation until ﬁrst event (graft failure, a second trans-
plantation, or death from any cause, whichever occurred ﬁrst) or last
follow-up for surviving patients.
Statistical Analysis
Continuous data were presented as median values and ranges, and
categorical data were expressed as frequencies and percentages. OS and TFS
were calculated using Kaplan-Meier curves and were compared between
the levels of covariates using log-rank test statistic, and 95% conﬁdence
intervals (CI) were computed through log-transformed method. We applied
the Cox proportional hazards model with a backward selection method toassess the multiple predictors of OS and TFS. Covariates with P values less
than .10 in the univariate analyses were candidates to enter the multivari-
able model. Also, variables that were simultaneously associated with type of
gene mutation and OS or TFS with P values less than .20 were considered
potential confounders for genemutation. The effects of covariates on OS and
TFS were reported as hazard ratios (HR) with a 95% CI. The proportional
hazards assumption was checked using the chi-square test of correlation
coefﬁcient between transformed survival time and Schoenfeld residuals.
The “survival” package in R software, version 3.0.0 [25], was used to analyze
the survival data.RESULTS
Patient Characteristics and b-globin Gene Mutations
A total of 89 patients were recruited for the study. Two
patients were dropped from the study because of difﬁculties
in access (they were living out of country). The source of
stem cells was bone marrow in 30 patients and peripheral
blood in 57 patients. The characteristics of the 87 patients
analyzed are summarized in Table 1.
Because the patients had various combinations
of b-globin gene mutations and to simplify genotype-
ephenotype analysis, the genotypes were classiﬁed into
2 groups: homozygous and compound heterozygous
mutations. Sixty-two (71%) patients had homozygous
mutations in the b-globin gene. In this group of 62 pa-
tients, intervening sequence II-I was the most prevalent
mutation (40 alleles, 32%), followed by mutations at
Table 2
b-Globin Gene Mutations
Mutation Homozygous (62
patients, 124 alleles)
Compound
Heterozygous (25
patients, 50 alleles)
IVS II-1 40 17
Codons 36-37 24 6
IVS I 5 22 2
Frame shifts 8-9 6 6
Codon 44 6 2
Codon 5 4 3
Frame shifts 36-37 4 1
IVS I 6 2 3
IVS I 25bpdel 4 1
Codon 22 2 2
IVS II 745 2 1
Codon 15 2 0
IVS I 128 2 0
Codon 8 2 0
IVS I 110 0 2
Codons 37-38-39 2 0
Codons 25-26 0 1
Deletion 0 1
Codon 39 0 1
Connection domain 16 0 1
IVS indicates intervening sequence.
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b-globin gene mutations is shown in Table 2.
Survival and Factors Predicting Survival
With a median follow-up of 12 months, the TFS and OS
probabilities were 82.5% (95% CI, 74.5% to 91.3%) and 89.9%
(95% CI, 83.5% to 96.9%), respectively. Acute GVHD (grades I
to IV) was observed in 39 patients (45%). During the follow-
up period, a total of 9 patients died (7 from GVHD and 2 from
infection).
In univariate analysis, younger recipient and donor age
as well as Pesaro class I or II status were associated with
signiﬁcantly higher 1-year OS and TFS rates (Table 3).Table 3
Univariate Effects of Covariates on OS and TFS
Variables Group
Patient age
Sex Male
Female
Pesaro classiﬁcation I, II
III
Mutation type Compound heterozygous
Homozygous
Donor age
Donor sex Male
Female
Donor-recipient sex matching Unmatched
Matched
Donor-recipient relationship Other relative
Sibling
Blood group matching Unmatched
Matched
Stem cell source Peripheral blood
Bone marrow
Donor-recipient age difference Donor younger than recipient
Donor older than recipient <12 yr
Donor older than recipient 12 yr
Acute GVHD No
Yes
Chronic GVHD No
YesDonor-recipient age difference was signiﬁcantly associated
with TFS (P ¼ .032). A donor-recipient age difference of less
than 12 years (the median) was signiﬁcantly associated
with a higher TFS rate compared with a donor-recipient age
difference of greater than 12 years (HR, .088; 95% CI, .011 to
.686; P ¼ .02).
We identiﬁed that among patients with intervening
sequence II-I mutation in the b-globin gene, homozygous
mutation holders had a higher TFS rate than those with
compound heterozygous mutations in the b-globin gene
(homozygous mutation 94.4% [95% CI, 84.4% to 100%] versus
compound heterozygous mutations 70.6% [95% CI, 51.9% to
95.9%], P ¼ .048). Because of various combinations of
b-globin gene mutations, we couldn’t analyze other muta-
tions separately; therefore, we compared homozygous with
compound heterozygous mutations in all b-globin gene
mutations.
Table 4 compares variables between gene mutation
levels. Age was the only variable that differed between the
levels of gene mutation. However, there was no difference
in the clinical status of patients (evaluated by Pesaro
classiﬁcation) among the 2 groups. The survival analysis of
all patients revealed a highly signiﬁcant association be-
tween homozygous mutation and a higher TFS rate (HR,
.25; 95% CI, .09 to .71; unadjusted P ¼ .009). After adjust-
ment of this association for age, it remained signiﬁcant
(HR, .328; 95% CI, .113 to .952; P ¼ .04). Further analysis
showed that better TFS in homozygous b-globin mutation
holders may contribute to less graft rejection (HR, .166;
95% CI, .034 to .826; P ¼ .028). Treatment-related mortality
was not signiﬁcantly different in homozygous versus
compound heterozygous b-globin mutations holders (HR,
.403; 95% CI, .108 to 1.503; P ¼ .176). The ﬁnal multivariable
model (Table 5) demonstrated that the main determinants
of a higher TFS rate were homozygous gene mutation,
younger donor than recipient, and Pesaro class I or II
status.OS TFS
HR (95% CI) P Value HR (95% CI) P Value
1.24 (1.03-1.51) .025 1.29 (1.11-1.50) .001
1 .589 1 .897
.69 (.17-2.75) .93 (.33-2.62)
1 .013 1 .001
4.70 (1.22-18.03) 6.14 (2.15-17.55)
1 .27 1 .009
.48 (.13-1.83) .25 (.09-.71)
1.06 (1.01-1.11) .014 1.08 (1.04-1.13) <.001
1 .682 1 .675
1.31 (.35-4.89) 1.24 (.45-3.43)
1 .786 1 .473
1.20 (.32-4.46) 1.46 (.52-4.10)
1 .069 1 .022
.3 (.07-1.21) .29 (.10-.84)
1 .619 1 .361
.72 (.19-2.69) .62 (.23-1.72)
1 .651 1 .763
1.35 (.36-5.07) 1.17 (.42-3.31)
1 .136 1 .032
.48 (.04-5.31) .55 .23 (.03-2.03) .184
3.03 (.61-15.17) .177 2.58 (.81-8.28) .11
1 .206 1 .535
2.36 (.59-9.46) .72 (.26-2.03)
1 .635 1 .683
1.46 (.30-7.01) .73 (.17-3.25)
Table 4
Comparison of Variables between Gene Mutation Levels
Variables Group Compound Heterozygous (n¼ 25) Homozygous (n ¼ 62) P Value
Freq. % Freq. %
Sex Male 16 64.0% 33 53.2% .359
Female 9 36.0% 29 46.8%
Pesaro classiﬁcation I/II 17 68.0% 47 75.8% .455
III 8 32.0% 15 24.2%
Donor sex Male 12 48.0% 34 54.8% .563
Female 13 52.0% 28 45.2%
Donor-recipient sex matching Unmatched 12 48.0% 31 50.0% .866
Matched 13 52.0% 31 50.0%
Donor-recipient relationship Other relative 3 12.0% 9 14.5% 1.000
Sibling 22 88.0% 53 85.5%
Blood group matching Unmatched 9 36.0% 21 33.9% .850
Matched 16 64.0% 41 66.1%
Stem cell source Peripheral blood 16 64.0% 41 66.1% .850
Bone marrow 9 36.0% 21 33.9%
Donor-recipient age difference Donor younger than recipient 10 40.0% 17 27.4% .472
Donor older than recipient <12 yr 7 28.0% 24 38.7%
Donor older than recipient 12 yr 8 32.0% 21 33.9%
Acute GVHD No 15 60.0% 33 53.2% .565
Yes 10 40.0% 29 46.8%
Age at treatment Median (range) 10 (4-15) 7 (2-15) .003
Donor age Median (range) 13 (2.5-43) 14 (2.5-53) .642
Follow-up, mo Median (range) 11 (2-75) 12 (2-106)
Freq. indicates frequency.
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Our results show that the type of b-globin mutation
(homozygous versus compound heterozygous) as well as the
Pesaro classiﬁcation and donor-recipient age difference are
able to predict survival outcomes of HSCT in b-TM patients.
To our knowledge, we are the ﬁrst to report that homozygous
mutation in the b-globin gene is a prognostic biomarker of a
favorable TFS after HSCT in b-TM patients.
Improvements in transplantation technologies and pa-
tient care increased the OS and TFS of thalassemia patients to
greater than 90% and more than 80%, respectively [9]. With
pretransplantation risk assessment by Pesaro group, b-TM
patients were divided into 3 risk classes based on their
clinical risk factors, including liver size, presence of liver
ﬁbrosis, and chelation history [7,8,26]. Pesaro risk stratiﬁca-
tion has been established and used by many bone marrow
transplantation programs worldwide; however, results of
some studies were different from Pesaro results [12-14],
which might be explained by differences in the patients’
genetic proﬁles.
The molecular pathophysiology of thalassemia was iden-
tiﬁed during the 1970s [27-29] and was characterized later
with the advancement of molecular analysis techniques. Pre-
vious studies have shown that the molecular defects in b-TM
are heterogeneous [30-32] and this heterogeneity might beTable 5
Multiple Predictors of TFS and OS
Variables Group TFS
Ha
Mutation Homozygous 1
Compound heterozygous 3.8
Donor-recipient age difference Donor younger than recipient 1
Donor older than recipient <12 yr .40
Donor older than recipient 12 yr 3.1
Pesaro classiﬁcation I, II 1
III 4.3
Donor-recipient relationship Other relative
Siblingassociated with disease severity in b-TM [16,17]. Also, a
possible association between genotype and response to hy-
droxyurea therapy in b-TM has been suggested in some
studies [33,34]. In addition, different distributions of b-globin
mutations are expected in different patient populations
[35,36]. This different geographical prevalence of b-globin
mutations [37,38]might explain the different clinical outcome
in these patients. Therefore, we hypothesized that genotype
may affect the HSCT outcome in b-TM. In our study, patients
with compound heterozygous b-globin mutation showed a
nearly 4-times worse TFS compared with those with homo-
zygous mutations. Our understanding of the mechanisms and
details of this effect is limited and needs further investigation.
Also, the heterogeneity of b-globin mutations limited our
ability to analyze each mutation individually. Analysis of the
outcome for each mutation can reveal more details of the role
of b-globin mutation on treatment outcome. In addition,
future studies might uncover other molecular determinants of
outcome in b-TM.
Although limited by the small sample size and short
median follow-up time, our study is the ﬁrst to underscore
the role of b-globin gene mutation in TFS after trans-
plantation for patients with b-TM. Further large multicenter
studies are needed to clarify this role and to conﬁrm our
results.OS
zard Ratio (95% CI) P Value Hazard Ratio (95% CI) P Value
.014
3 (1.31-11.20)
.045
1 (.043-3.72) .421
2 (.954-10.20) .06
.008 1 .007
1 (1.46-12.74) 6.87 (1.67-28.19)
1 .021
.18 (.04-.77)
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